Story thread · 8 reports / 4 sources
STAT+: Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field
statnews.com · 4d
The back-to-back failures of cardiovascular drugs from Novartis and Novo Nordisk made headlines. They could also have a chilling effect across the industry.
First report: Eaton Shares Rise After UBS Upgrade to Buy — finance.yahoo.com, 6d
The coverage
- Morgan Stanley downgrades Novo Nordisk stock rating on growth concerns
investing.com · 4d
- Eaton upgraded at UBS as margins improve, AI power demand accelerates
seekingalpha.com · 6d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.